Connor, Clark & Lunn Investment Management (CC&L)
CRDF icon

Connor, Clark & Lunn Investment Management (CC&L)’s Cardiff Oncology CRDF Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,105
Closed -$54K – 1435
2024
Q1 		$54K Buy
+10,105
New +$26.9K ﹤0.01% 1487

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CRDF Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Cardiff Oncology (CRDF) in Q2 2024, closing a stake of 10,105 shares — an estimated $54K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CRDF in Q1 2024 and held it in 1 quarter. The position peaked at $54K in Q1 2024. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Cardiff Oncology position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 10,105 Cardiff Oncology shares in Q2 2024, an estimated $54K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Cardiff Oncology in Q1 2024 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Cardiff Oncology position peaked at $54K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.